Abstract
Biologics targeting specific cytokines and pathways have revolutionized the management of patients with chronic inflammatory diseases such as psoriasis. Although generally very safe, these treatments have their limitations and, surprisingly, can aggravate pre-existing or induce novel inflammatory diseases. Here, we present a cohort of psoriasis patients developing new onset eczema during anti-IL17 treatment, an intriguing side effect of IL-17 blockade with a largely unknown pathogenesis. The coexistence of psoriasis and eczema in a single patient is uncommon given their distinct and opposing immune mechanisms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
